Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00730626
Other study ID # INAF-119
Secondary ID
Status Completed
Phase N/A
First received August 6, 2008
Last updated June 19, 2009
Start date August 2008
Est. completion date May 2009

Study information

Verified date June 2009
Source Laval University
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the dose-response effect of a yogurt containing a combination of bifidobacterium Lactis (BB-12) and Lactobacillus Acidophilus (LA-5) and green tea extract on markers of the immune system and gut health in healthy subjects. We hypothesize that the response of the immune function will be dose-dependent of the probiotics found in the fermented yogurt.


Description:

There is an increasing list of food containing probiotics on the market. Several studies have emphasized the health benefits of single probiotics, particularly on the immune system. However, it is unclear how a combination of two different probiotics complemented with green tea extract can beneficially modify markers of the immune.

The aim of this study is to determine the dose-response effect of a yogurt containing a combination of bifidobacterium lactis (BB-12) and Lactobacillus Acidophilus LA-5 and green tea extract on immune system in healthy subjects. More specifically, this randomized, parallel placebo controlled study will investigate the impact of increasing doses (109 and 1010) of these probiotics on phagocytosis activity, oxidative metabolism and on the antipneumococcics antibody specific serotype response S. pneumoniae vaccination. Finally, this study will also examine the effect of increasing dose of these probiotics on intestinal microflora and blood lipids.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date May 2009
Est. primary completion date December 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between 18 to 55 years

- Healthy individuals, non-smokers

- BMI between 18 and 35 kg/m2

- Stable weight (+/- 5kg) for 3 months before randomisation

- Agree to receive a vaccine Pneumovax 23®

Exclusion Criteria:

- Pregnant or lactating woman

- Previous history of cardiovascular disease

- Diabetes

- Kidney or liver disease

- Gastrointestinal disorders or diseases

- Endocrine disorders or diseases

- Allergy

- Subjects taking hypolipidemic drugs, antidepressant, medication for high blood pressure, for inflammation or auto-immune diseases.

- Subject who have receive antipneumococcics vaccine in the year before randomisation.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Yogurt with 1X10E9 BB-12 and LA-5
100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
Yogurt with 1X10E10 BB-12 and LA-5
100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
Yogurt Placebo
100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.

Locations

Country Name City State
Canada Institute of Nutraceuticals and Functional Foods (INAF), Laval University Quebec

Sponsors (4)

Lead Sponsor Collaborator
Laval University Aliments ULTIMA Foods Inc., McGill University, TransBiothec

Country where clinical trial is conducted

Canada, 

References & Publications (10)

Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 2000 Mar;54(3):263-7. — View Citation

de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, Ott S, Hampe J, Schreiber S, Heller K, Schrezenmeir J. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006 Nov 10;24(44-46):6670-4. Epub 2006 Jun 6. — View Citation

Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001 Dec;74(6):833-9. — View Citation

Kukkonen K, Nieminen T, Poussa T, Savilahti E, Kuitunen M. Effect of probiotics on vaccine antibody responses in infancy--a randomized placebo-controlled double-blind trial. Pediatr Allergy Immunol. 2006 Sep;17(6):416-21. — View Citation

Olivares M, Díaz-Ropero MP, Gómez N, Lara-Villoslada F, Sierra S, Maldonado JA, Martín R, Rodríguez JM, Xaus J. The consumption of two new probiotic strains, Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711, boosts the immune system of healthy humans. Int Microbiol. 2006 Mar;9(1):47-52. — View Citation

Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007 Mar;23(3):254-60. — View Citation

Roller M, Clune Y, Collins K, Rechkemmer G, Watzl B. Consumption of prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis has minor effects on selected immune parameters in polypectomised and colon cancer patients. Br J Nutr. 2007 Apr;97(4):676-84. — View Citation

Schiffrin EJ, Brassart D, Servin AL, Rochat F, Donnet-Hughes A. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr. 1997 Aug;66(2):515S-520S. — View Citation

Taylor AL, Hale J, Wiltschut J, Lehmann H, Dunstan JA, Prescott SL. Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. Clin Exp Allergy. 2006 Oct;36(10):1227-35. — View Citation

Winkler P, de Vrese M, Laue Ch, Schrezenmeir J. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. Int J Clin Pharmacol Ther. 2005 Jul;43(7):318-26. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Phagocytosis activity and oxidative metabolism in phagocytes. 6 weeks after vaccination No
Secondary antipneumococcics antibody specific serotype response to S. pneumoniae vaccination. 6 weeks after yogurt consumption and vaccination No
Secondary Intestinal microflora characteristics. 4 weeks after yogurt consumption No
Secondary Influence of blood lipids. After 4 weeks and 10 weeks of yogurt consumption No
See also
  Status Clinical Trial Phase
Completed NCT02277080 - The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids
Active, not recruiting NCT05026242 - Effects of Almond Consumption on Innate and Adaptive Immune System N/A
Completed NCT04701502 - Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 Phase 2
Terminated NCT05133128 - An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours. N/A
Recruiting NCT05792137 - Postprandial Monocyte Study N/A
Completed NCT05329337 - Link Between the Peripheral Mononuclear Cells' Capacity to Induce Insulin Resistance and Hyperinsulinemia N/A
Completed NCT06263686 - Evaluation of the Effects of Routine Intake of Fresh vs- Pasteurized Yoghurt on the Immune System in Healthy Adults N/A
Recruiting NCT04772794 - Immunologic Effect of Fraction of Inspired Oxygen N/A
Recruiting NCT06312423 - Safety and Pharmacokinetics of IMT504, an Immunomodulator and Tissue Repair Inducer Phase 1
Completed NCT00753402 - The Effects of Epinephrine in Endotoxemia in Normal Volunteers Phase 1
Completed NCT00820989 - Inflammation and the Host Response to Injury (In Healthy Volunteers) Phase 1
Completed NCT05221996 - Minimal-Dose Resistance Training for Improving sIgA and Cortisol N/A
Completed NCT04275440 - Effects of Caloric Restriction and Exercise on Body Weight, Immune Function, and Intestinal Flora N/A
Recruiting NCT06109337 - Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder
Recruiting NCT05648136 - Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage N/A
Completed NCT06190379 - Aromatherapy for Upper Respiratory Health N/A
Recruiting NCT05334888 - Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach
Recruiting NCT06400212 - CytoHealth - A Study of the Inflammatory Response to Exercise N/A